Linn Y L, Choke E T C, Yap C J Q, Tan R Y, Patel A, Tang T Y
Department of Vascular Surgery, Singapore General Hospital, Singapore, Singapore.
Department of General Surgery, Sengkang General Hospital, Singapore, Singapore.
CVIR Endovasc. 2022 Jun 24;5(1):29. doi: 10.1186/s42155-022-00308-z.
Sirolimus-coated balloons (SCB) have demonstrated much promise as an alternative drug eluting device to the existing paclitaxel coated balloon platforms for the treatment of peripheral arterial disease (PAD). They have been well tested pre-clinically and have demonstrated anti-restenotic effects as well as clinical safety in its use for treatment of coronary artery disease. The existing approved SCBs have thus far demonstrated good short-term patency (12-months) and did not exhibit any major adverse events or device related shortcomings in its use for treatment of PAD. There are several studies ongoing which aim to further investigate the efficacy of existing SCBs and establish a direct comparison of its outcomes compared with plain balloon angioplasty. Also, SCB utility to salvage failing arteriovenous fistulas for haemodialysis patients has also been explored. We review the current progress made in the establishment of SCB in the treatment of PAD as well as highlight ongoing studies investigating the role of SCB in various settings.
西罗莫司涂层球囊（SCB）作为一种替代药物洗脱装置，相较于现有的紫杉醇涂层球囊平台，在治疗外周动脉疾病（PAD）方面已展现出巨大潜力。它们在临床前已得到充分测试，并在用于治疗冠状动脉疾病时显示出抗再狭窄作用以及临床安全性。迄今为止，现有的已获批SCB在治疗PAD时展现出良好的短期通畅率（12个月），且未出现任何重大不良事件或与器械相关的缺陷。目前有多项研究正在进行，旨在进一步探究现有SCB的疗效，并与普通球囊血管成形术的结果进行直接比较。此外，也已探讨了SCB在挽救血液透析患者功能衰竭的动静脉瘘方面的效用。我们回顾了在将SCB用于治疗PAD方面取得的当前进展，并着重介绍正在进行的研究，这些研究调查了SCB在各种情况下的作用。
